Noonan syndrome - a new survey

Area of Science:

• Genetics and Molecular Biology
• Pediatrics
• Oncology

Background:

• Noonan syndrome (NS) is a genetically heterogeneous autosomal dominant disorder.
• It presents with a wide spectrum of clinical manifestations including short stature, distinctive facial features, congenital heart defects, developmental delays, and increased cancer risk.
• NS shares overlapping features with other RASopathies, such as LEOPARD syndrome, cardio-facio-cutaneous syndrome, and Costello syndrome.

Purpose of the Study:

• To summarize the key aspects of Noonan syndrome, including its clinical heterogeneity and genetic underpinnings.
• To highlight the diagnostic approaches and the importance of molecular testing.
• To underscore the increased risk of malignancies in patients with Noonan syndrome.

Main Methods:

• Review of clinical and genetic features of Noonan syndrome.
• Discussion of diagnostic criteria and molecular testing strategies.
• Examination of the association between Noonan syndrome and oncogenesis.

Main Results:

• Germline mutations within the RAS-MAPK signaling pathway are implicated in Noonan syndrome and related disorders.
• Diagnosis relies on clinical assessment, with molecular testing recommended for confirmation.
• Next-generation sequencing is identified as the optimal method for comprehensive genetic analysis due to the numerous associated genes.
• Patients with Noonan syndrome exhibit an elevated risk for leukemia and certain solid tumors.

Conclusions:

• Noonan syndrome is a complex RASopathy requiring a multi-faceted diagnostic approach.
• Molecular genetic testing is essential for confirming the diagnosis and understanding the underlying genetic cause.
• Early identification and management are critical due to potential complications, including an increased risk of cancer.